InterCure (NASDAQ:INCR) Stock Price Down 0.2% – Should You Sell?

InterCure Ltd. (NASDAQ:INCR) shares dropped 0.2% during mid-day trading on Thursday . The stock traded as low as $5.23 and last traded at $5.24. Approximately 5,220 shares changed hands during trading, a decline of 88% from the average daily volume of 44,050 shares. The stock had previously closed at $5.25.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised InterCure from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 9th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, InterCure currently has an average rating of “Sell”.

InterCure Price Performance

The company has a market cap of $57.33 million, a P/E ratio of 34.93 and a beta of 1.42. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.97 and a current ratio of 1.48. The firm’s fifty day moving average is $4.97 and its two-hundred day moving average is $4.56.

InterCure Company Profile

InterCure Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.

Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives.